<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and the safety of a combination regimen using cefbuperazone (CBPZ) and <z:chebi fb="0" ids="2637">amikacin</z:chebi> (AMK) were evaluated in severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty two patients were subjected to this combination therapy; among these, 18 patients were evaluable for the effectiveness </plain></SENT>
<SENT sid="2" pm="."><plain>They included 9 cases of <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 5 cases of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 2 cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and 2 cases of angio-<z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> with <z:e sem="disease" ids="C0259744" disease_type="Disease or Syndrome" abbrv="">dysproteinemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Excellent responses were obtained in 5 patients and good responses in 5 patients, with a total effectiveness of 55.6% </plain></SENT>
<SENT sid="4" pm="."><plain>Efficacy rates for individual types of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were; 2/2 in <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 6/14, or 42.9% in suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 1/1 in <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo>, and and 1/1 in upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The combination treatment was also effective in 4 of 6 cases in which neutrophil counts were less than 500/mm3 prior to therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Side effects were observed in only one patient </plain></SENT>
<SENT sid="7" pm="."><plain>Mild <z:hpo ids='HP_0000093'>proteinuria</z:hpo> occurred in a 80-year-old male in 6 days after the regimen was started, but was not serious </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate that a combination of CBPZ and AMK is safe and effective for the treatment of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> even in patients with compromised immunodefenses </plain></SENT>
</text></document>